Potential impacts of diabetes mellitus and anti-diabetes agents on expressions of sodium-glucose transporters (SGLTs) in mice
Endocrine · 2021-12 · 74 (3) · 571-581
DOI: 10.1007/s12020-021-02818-7 ↗Kurz gefasst
Fachartikel in der Zeitschrift Endocrine, online erschienen am 13.07.2021. Verfasst von Ziqi Hu und 4 weiteren Autor:innen. Beteiligte Einrichtung: Affiliated Hospital of Integrated Traditional Chinese and Western Medicine, Nanjing University of Chinese Medicine, Nanjing, China. Hauptthemen laut MEDLINE: Diabetes Mellitus, Experimental, Diabetes Mellitus, Type 2, Sodium-Glucose Transport Proteins. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 24 Literaturangaben. Gefördert von: Natural Science Foundation of China.
Themen: Diabetes mellitus
Abstract (Originalsprache)
PURPOSE: Sodium-glucose transporters (SGLTs) are important targets for therapeutic intervention of type 2 diabetes. This study aims to evaluate the physiological influences of diabetes mellitus and the potential impacts of metformin and fluoxetine on SGLTs expressions. METHODS: Alterations of SGLT1 and SGLT2 were measured in organs involved in glucose homeostasis (kidney, intestine, liver and pancreas) of streptozotocin (STZ) and high-fat diet (HFD) induced diabetic mice by western blotting and real-time PCR (RT-PCR) respectively. RESULTS: In kidney, duodenal segments of intestine, liver, and pancreas of HFD diabetic mice, expressions of SGLT2 were all elevated compared to control mice. The level of SGLT1 was significantly increased in intestine, but was decreased in pancreas. SGLT1 expression in kidney was unaffected, and SGLT1 was undetectable in hepatocytes. Similar results were obtained in STZ diabetic mice. More importantly, here we noticed metformin decreased levels of SGLT2 in kidney, intestine, and pancreas of HFD mice markedly. Expressions of SGLT1 in intestine and pancreas were reduced by metformin as well. In contrast, fluoxetine increased abundances of SGLT2 and SGLT1 in kidney of HFD mice, but decreased SGLT1 expression in intestine. CONCLUSIONS: The present study provided evidence that expressions of SGLT1 and SGLT2 were significantly modulated by diabetes mellitus as well as by metformin and fluoxetine, which indicated the efficacy of SGLT2 inhibitors might be impacted by these factors.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Affiliated Hospital of Integrated Traditional Chinese and Western Medicine, Nanjing University of Chinese Medicine, Nanjing, China.
- Key Laboratory of New Drug Delivery System of Chinese Materia Medica, Jiangsu Province Academy of Traditional Chinese Medicine, Nanjing, China.
- Affiliated Hospital of Integrated Traditional Chinese and Western Medicine, Nanjing University of Chinese Medicine, Nanjing, China. shuluan2006@hotmail.com.
- Key Laboratory of New Drug Delivery System of Chinese Materia Medica, Jiangsu Province Academy of Traditional Chinese Medicine, Nanjing, China. shuluan2006@hotmail.com.
Förderung
- Natural Science Foundation of China
Zitieren
APA
Hu, Z., Liao, Y., Wang, J., Wen, X., & Shu, L. (2021). Potential impacts of diabetes mellitus and anti-diabetes agents on expressions of sodium-glucose transporters (SGLTs) in mice. Endocrine, 74(3), 571-581. https://doi.org/10.1007/s12020-021-02818-7
Vancouver
Hu Z, Liao Y, Wang J, Wen X, Shu L. Potential impacts of diabetes mellitus and anti-diabetes agents on expressions of sodium-glucose transporters (SGLTs) in mice. Endocrine. 2021;74(3):571-581. doi:10.1007/s12020-021-02818-7
BibTeX
@article{Hu2021,
author = {Hu, Ziqi and Liao, Yanjun and Wang, Jing and Wen, Xiaohua and Shu, Luan},
title = {Potential impacts of diabetes mellitus and anti-diabetes agents on expressions of sodium-glucose transporters (SGLTs) in mice},
journal = {Endocrine},
year = {2021},
volume = {74},
number = {3},
pages = {571--581},
doi = {10.1007/s12020-021-02818-7}
}
EUVIMED